Bausch + Lomb Corp.

As of October 3, 2025, Bausch + Lomb Corp. shows a mildly bullish trend supported by the weekly MACD and daily moving averages, but caution is advised due to bearish monthly indicators and underperformance compared to the S&P 500.

As of October 3, 2025, Bausch + Lomb Corp. shows a mildly bullish trend supported by weekly indicators, despite mixed longer-term signals and underperformance compared to the S&P 500, with year-to-date returns of -15.84% versus the S&P's 14.18%.

As of September 8, 2025, Bausch + Lomb Corp. shows a neutral technical trend with mixed signals, underperforming the S&P 500 year-to-date by -14.84% compared to the S&P's 12.22%.

As of May 3, 2023, Bausch + Lomb Corp. is considered overvalued and risky due to its low Price to Book Value of 0.65, high EV to EBITDA ratio of 14.88, poor ROCE of 1.42%, and underperformance compared to the S&P 500, with a year-to-date return of -14.84%.

As of May 3, 2023, Bausch + Lomb Corp. is considered overvalued and risky due to its negative profitability metrics, low Price to Book Value, high EV to EBITDA ratio, and significant underperformance compared to the S&P 500.

As of June 9, 2025, the market trend is mildly bearish, indicated by daily moving averages and weekly Bollinger Bands, despite a mildly bullish weekly MACD, with overall performance lagging behind the S&P 500 year-to-date.

Bausch + Lomb Corp. is a small-cap company in the Pharmaceuticals & Biotechnology industry, reporting net sales of $1.137 billion and a net loss of $211 million as of March 2025. Key metrics include a market cap of $4.09 billion, a debt-to-equity ratio of 0.73, and a return on equity of -3.98%.

As of Jun 18, Bausch + Lomb Corp. has a market capitalization of $4.09 billion, with recent net sales of $4.83 billion and a net profit of -$353 million.